Jonathan Pachter

Jonathan Pachter

Company: Verastem. inc

Job title: CSO


Tumor/Biomarker-Specific Combination Strategies with the RAF/MEK Clamp VS-6766 4:30 pm

VS-6766 blocks the RAS pathway through a novel RAF/MEK clamp mechanism Rationale for ongoing combination trials with VS-6766 with defactinib or everolimus Novel VS-6766 combinations for tumor/biomarkerspecific patient populationsRead more

day: Day One Track H

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.